Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 13

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

401

HTML

2581

Figures (1-1)

212

Tables (1-4)

201

Sum=3395

Jul 1, 2004 (publication date) through Nov 30, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Jul 1, 2004; 10(13): 1902-1906
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1902

Table 1 Lymphocytes proliferation assay (mean ± SD, n = 27)

	³*H-TdR counts (cpm)*
	Peptide1	Peptide2	Peptide3^b	Negative controls
PBMCs from healthy donors	4001.6 ± 328.3	5882.6 ± 397.2	10497.6 ± 859.7	2556.3 ± 211.3
PBMCs from chronic hepatitis patients	3967.5 ± 285.9	4912.3 ± 421.1	7696.2 ± 781.8	2327.6 ± 169.2

^bP < 0.01 vs negative control and peptide1 and 2 groups.

Citation: Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD₈⁺ CTL-mediated cytotoxicity in HLA-A2⁺ human PBMCs. World J Gastroenterol 2004; 10(13): 1902-1906
URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1902.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1902